Wuxi Biologics Holdings Limited - Net Worth and Insider Trading

Wuxi Biologics Holdings Limited Net Worth

The estimated net worth of Wuxi Biologics Holdings Limited is at least $6.8 Billion dollars as of 2024-06-22. Wuxi Biologics Holdings Limited is the 2101 Beneficial owner of WuXi Biologics (Cayman) Inc and owns about 584,191,133 shares of WuXi Biologics (Cayman) Inc (HKSE:02269) stock worth over $6.8 Billion. Details can be seen in Wuxi Biologics Holdings Limited's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Wuxi Biologics Holdings Limited has not made any transactions after 2023-01-19 and currently still holds the listed stock(s).

Transaction Summary of Wuxi Biologics Holdings Limited

Wuxi Biologics Holdings Limited Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Wuxi Biologics Holdings Limited owns 1 companies in total, including WuXi Biologics (Cayman) Inc (HKSE:02269) .

Click here to see the complete history of Wuxi Biologics Holdings Limited’s form 4 insider trades.

Insider Ownership Summary of Wuxi Biologics Holdings Limited

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:02269	WuXi Biologics (Cayman) Inc	2023-01-19	2101 Beneficial owner

Wuxi Biologics Holdings Limited Latest Holdings Summary

Wuxi Biologics Holdings Limited currently owns a total of 1 stock. Wuxi Biologics Holdings Limited owns 584,191,133 shares of WuXi Biologics (Cayman) Inc (HKSE:02269) as of January 19, 2023, with a value of $6.8 Billion.

Latest Holdings of Wuxi Biologics Holdings Limited

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:02269	WuXi Biologics (Cayman) Inc	2023-01-19	584,191,133	11.60	6,776,617,143

Holding Weightings of Wuxi Biologics Holdings Limited

Wuxi Biologics Holdings Limited Form 4 Trading Tracker

According to the SEC Form 4 filings, Wuxi Biologics Holdings Limited has made a total of 2 transactions in WuXi Biologics (Cayman) Inc (HKSE:02269) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in WuXi Biologics (Cayman) Inc is the sale of 56,000,000 shares on January 19, 2023, which brought Wuxi Biologics Holdings Limited around $0.

Insider Trading History of Wuxi Biologics Holdings Limited

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Wuxi Biologics Holdings Limited Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Wuxi Biologics Holdings Limited Ownership Network

Ownership Network List of Wuxi Biologics Holdings Limited

No Data

Ownership Network Relation of Wuxi Biologics Holdings Limited

Wuxi Biologics Holdings Limited Owned Company Details

What does WuXi Biologics (Cayman) Inc do?

Who are the key executives at WuXi Biologics (Cayman) Inc?

Wuxi Biologics Holdings Limited is the 2101 Beneficial owner of WuXi Biologics (Cayman) Inc. Other key executives at WuXi Biologics (Cayman) Inc include 2201 Interest of corporation controlled by you BlackRock, Inc. , 2201 Interest of corporation controlled by you Jpmorgan Chase & Co. , and 2201 Interest of corporation controlled by you Li Ge .

WuXi Biologics (Cayman) Inc (HKSE:02269) Insider Trades Summary

Over the past 18 months, Wuxi Biologics Holdings Limited made 1 insider transaction in WuXi Biologics (Cayman) Inc (HKSE:02269) with a net sale of 56,000,000. Other recent insider transactions involving WuXi Biologics (Cayman) Inc (HKSE:02269) include a net purchase of 103,747,521 shares made by Jpmorgan Chase & Co. , a net sale of 0 shares made by BlackRock, Inc. , and a net sale of 0 shares made by Citigroup Inc. .

In summary, during the past 3 months, insiders sold 0 shares of WuXi Biologics (Cayman) Inc (HKSE:02269) in total and bought 39,637,531 shares, with a net purchase of 39,637,531 shares. During the past 18 months, 406,720,548 shares of WuXi Biologics (Cayman) Inc (HKSE:02269) were sold and 179,274,569 shares were bought by its insiders, resulting in a net sale of 227,445,979 shares.

WuXi Biologics (Cayman) Inc (HKSE:02269)'s detailed insider trading history can be found in Insider Trading Tracker table.

WuXi Biologics (Cayman) Inc Insider Transactions

No Available Data

Wuxi Biologics Holdings Limited Mailing Address

Above is the net worth, insider trading, and ownership report for Wuxi Biologics Holdings Limited. Currently GuruFocus does not have mailing address information for Wuxi Biologics Holdings Limited.

Discussions on Wuxi Biologics Holdings Limited

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.